- Home
- NDLS vs GDTC Comparison
NDLS vs GDTC Comparison
Compare NDLS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | GDTC |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 15.5M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NDLS | GDTC |
|---|---|---|
| Price | $0.86 | $0.94 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 424.3K | 38.4K |
| Earning Date | 03-05-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $494,087,000.00 | $573,193.00 |
| Revenue This Year | $2.29 | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $0.55 | $0.89 |
| 52 Week High | $1.74 | $3.68 |
Technical Indicators
Market Signals| Indicator | NDLS | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 20.48 |
| Support Level | $0.73 | $0.89 |
| Resistance Level | $0.89 | $1.39 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 79.61 | 7.13 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.